Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Som. D. Mukherjee"'
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 2743-2750 (2023)
Healthcare systems in Canada and elsewhere have identified the need to develop methods to effectively and safely transition appropriate cancer survivors to primary care. It is generally accepted that survivors with a low risk of adverse events, inclu
Externí odkaz:
https://doaj.org/article/62e86111b3cb4cafae56399ac21eddbf
Autor:
Karen M. Zhang, Som D. Mukherjee, Gregory Pond, Michelle I. Roque, Ralph M. Meyer, Jonathan Sussman, Peter M. Ellis, Denise Bryant-Lukosius
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5354-5366 (2024)
Objective: Understanding both the positive and negative psychological outcomes among cancer patients during the pandemic is critical for planning post-pandemic cancer care. This study (1) examined levels of psychological distress and post-traumatic g
Externí odkaz:
https://doaj.org/article/47e462277fbb4c969bae1b867bc8413f
Autor:
Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1803-1816 (2024)
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps de
Externí odkaz:
https://doaj.org/article/3be7b57ba6b54e2e8cadf719163522c8
Autor:
Muhammad Mustafa Alhussein, MD, Abir Mokbel, MD, MSc, Tammy Cosman, RN(EC), PhD, Nazanin Aghel, MD, Eric H. Yang, MD, Som D. Mukherjee, MD, Susan Dent, MD, Peter M. Ellis, MBBS, MMed, PhD, Sukhbinder Dhesy-Thind, MD, MSc, Darryl P. Leong, MBBS, MPH, M. Biostat, PhD
Publikováno v:
CJC Open, Vol 3, Iss 11, Pp 1372-1382 (2021)
Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well es
Externí odkaz:
https://doaj.org/article/19ebfb6c8fb04bf8886b70411a949d57
Autor:
Darryl P. Leong, MBBS, MPH, MBiostat, PhD, Tammy Cosman, PhD, Muhammad M. Alhussein, MD, Nidhi Kumar Tyagi, MBChB, Sarah Karampatos, MS, Carly C. Barron, MD, MS, Douglas Wright, MD, Vikas Tandon, MD, Patrick Magloire, MD, Philip Joseph, MD, David Conen, MD, MPH, P.J. Devereaux, MD, PhD, Peter M. Ellis, MBBS, MMed, PhD, Som D. Mukherjee, MD, MS, Sukhbinder Dhesy-Thind, MD, MS
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 1-10 (2019)
Objectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity. Background: Cardiotoxicity is the most common dose-limi
Externí odkaz:
https://doaj.org/article/853ece99bece43b0bf1ea0e673d30148
Autor:
Darryl P. Leong, Som D. Mukherjee
Publikováno v:
JACC: CardioOncology. 5:137-140
Autor:
Tina Hsu, Flávia De Angelis, Sohaib Al-Asaaed, Sanraj K Basi, Anna Tomiak, Debjani Grenier, Nazik Hammad, Jan-Willem Henning, Scott Berry, Xinni Song, Som D Mukherjee
Publikováno v:
Canadian Medical Education Journal, Vol 12, Iss 2 (2021)
Background: Globally there is a move to adopt competency-based medical education (CBME) at all levels of the medical training system. Implementation of a complex intervention such as CBME represents a marked paradigm shift involving multiple stakehol
Externí odkaz:
https://doaj.org/article/a30de386945749edafb82b7b00f69ff4
Autor:
Filipe Cirne, Coralea Kappel, Shijie Zhou, Som D. Mukherjee, Mahshid Dehghan, Jo-Anne Petropoulos, Darryl P. Leong
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:453-462
Most of the epidemiological data on prostate cancer risk factors come from high-income countries (HIC). Reducing exposure to prostate cancer modifiable risk factors may significantly lower PCa morbidity and mortality in LIC and MIC. The objective of
Autor:
Jehonathan H. Pinthus, Wilhelmina C. M. Duivenvoorden, Laurence Klotz, Som D. Mukherjee, D. Robert Siemens, Tamim Niazi, Vincent Fradet, William Foster, Emmanuelle Duceppe, Daniel Taussky, Robert Hamilton, Luke Lavallée, Ian Brown, Joseph Chin, Darin Gopaul, Anthony Wassef, Wassim Kassouf, Margot Davis, Philippe D. Violette, Steve Agapay, Kumar Balasubramanian, Rajibul Mian, Sumathy Rangarajan, Alp Sener, Bobby Shayegan, P. J. Devereaux, Darryl P. Leong
Publikováno v:
Journal of Urology. 207:1020-1028
Cardiovascular disease is a common cause of death in prostate cancer patients. Low testosterone is associated with increased cardiovascular risk in the general male population. We investigated the relationship between serum testosterone, cardiovascul
Autor:
Shijie Zhou, Filipe Cirne, Justin Chow, Arman Zereshkian, Louise Bordeleau, Sukhbinder Dhesy-Thind, Peter M Ellis, Som D Mukherjee, Nazanin Aghel, Darryl P Leong
Publikováno v:
The Oncologist.
Introduction Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable o